Novel Rx

Different factors are known to influence disease characteristics and outcomes in psoriatic arthritis (PsA). Recently, there is new evidence that sex-related differences play a role not only in…

The ACR Convergence 2024 meeting provided its attendees with vast information about disease pathophysiology, diagnosis and treatment covering both clinical and basic sciences. One of the hot topics…

Lots of lupus research and the New ACR Guidelines on Lupus Nephritis management were presented today. These and other highlights as featured on our Twitter (X) feed from ACR24 in Washington, DC.…

Glucagon-like peptide-1 receptor agonists (GLP-1Ra) have transformed the treatment landscape for type 2 diabetes and obesity. By enhancing insulin secretion, suppressing glucagon release, and slowing…

When the ACR Convergence 2024 abstract site went live, the first query I typed into the search bar was, “CAR-T.” I consider myself a CAR-T skeptic and would be surprised if the magical results…

This year at #ACR24, emulation trials are being presented.Are these ‘trials’ helpful, despite the biases that occur with observational data, or do they truly mimic the results of randomized…

Axial spondyloarthritis (axSpA) is a chronic inflammatory disease primarily affecting the spine and sacroiliac joints, causing back pain, stiffness, and reduced mobility. The disease includes both…

For many years glucocorticoids were the mainstay of our treatment of granulomatosis with polyangiitis (GPA). The paradigm shifted with cyclophosphamide and then again with rituximab, and we used less…

A recent study by Sparks et al (Abstract #0509) reveals evolving trends in disease-modifying antirheumatic drug (DMARD) usage for rheumatoid arthritis (RA) over two decades in the United States.…

ACR 2024 starts tomorrow. Here are a few previews of abstracts to be presented, along with my recommendations of sessions you don’t want to miss.Previews:Abstract Number: 2527 Efficacy and…